What Happens After Detox? Rehab, Medication and Continuing Treatment

What happens after detox often matters more for long-term outcome than the final day of withdrawal management. Detox can stabilize the body, but it does not remove craving, restore tolerance, treat psychiatric illness, change a high-risk home environment or teach the skills needed to prevent recurrence. The safest transition is usually a direct handoff into the next treatment level with medications, appointments and transportation already arranged.

The first days after detox can be particularly vulnerable. A patient may still be exhausted, anxious or craving substances, while the structure and monitoring of detox disappear abruptly. For people with opioid use disorder, reduced tolerance can also increase overdose risk if opioid use resumes.

After Detox at a Glance

The First 72 Hours: Why the Transition Is High Risk

The patient’s risk profile can change quickly after leaving a 24-hour setting. Sleep may still be poor, mood may be unstable and access to alcohol or drugs may return immediately. Family conflict, transportation problems or a missed prescription can derail the plan before the first follow-up appointment.

That is why same-day transfer or rapid follow-up is preferable when possible. The goal is to reduce the amount of unstructured time between stabilization and treatment.

Medication reconciliation before discharge

The discharge medication list should clearly show what was started, stopped or changed. The receiving clinician should know what the detox team administered and what needs to continue.

This is especially important for buprenorphine, methadone, psychiatric medication and benzodiazepine tapers. A patient recovering from several days of withdrawal and poor sleep should not be expected to reconstruct the treatment plan from memory.

What Must Continue After Detox by Substance

Opioids: overdose prevention and OUD medication

When opioids are stopped, tolerance can fall. If the person returns to a previously tolerated amount, respiratory depression can become more likely. This is one reason opioid withdrawal management without ongoing OUD treatment can be a high-risk endpoint.

Buprenorphine or methadone can continue after the detox episode. Naloxone or another approved opioid-overdose reversal medication should also be part of overdose-prevention planning.

Alcohol: transition into AUD treatment

ASAM explicitly states that alcohol-withdrawal management alone is not effective treatment for alcohol use disorder. Once acute withdrawal stabilizes, the patient should have a plan for behavioral treatment and consideration of medication.

SAMHSA identifies naltrexone, acamprosate and disulfiram as common medications for AUD. The appropriate choice depends on treatment goals, medical conditions, other medications and whether opioid treatment is also involved.

Benzodiazepines: the taper may continue

A higher-intensity withdrawal stay may stabilize the most dangerous part of benzodiazepine dependence without completing the entire taper. The 2025 ASAM-led guideline supports gradual individualized reduction.

The receiving clinician needs the current dose, taper plan and follow-up schedule. An abrupt medication gap at discharge can recreate withdrawal risk.

Choosing the Next Level of Care

The ASAM Fourth Edition uses a multidimensional assessment rather than automatically sending everyone from detox to residential treatment. The recommended level reflects withdrawal / medication needs, medical conditions, psychiatric conditions, substance-use risk, recovery environment and person-centered factors.

A patient with stable housing, strong support and good outpatient engagement may not need residential care. Another patient with repeated rapid return to use, homelessness or persistent psychosis may need a much more structured setting.

Residential treatment

Residential treatment provides a 24-hour living environment with structured addiction care. It can be appropriate when the patient needs separation from a high-risk environment, intensive behavioral treatment or greater support than outpatient care can provide.

Residential treatment is not automatically hospital-level care. Programs vary in medical and psychiatric capability, so medication and co-occurring-condition needs should be confirmed before transfer.

Outpatient treatment

Outpatient care can range from high-intensity programs with many treatment hours each week to standard counseling and medication visits. It allows the patient to live at home and practice recovery skills in the environment where substance use actually occurred.

Outpatient treatment works best when the home environment is reasonably safe, attendance is reliable and psychiatric or medical instability does not require continuous monitoring.

Recovery housing

A recovery residence can provide a substance-free living environment and peer structure. It can be especially useful when the patient’s previous housing involved active substance use or instability.

Recovery housing is not automatically a substitute for clinical treatment. Someone who still needs therapy, OUD medication, psychiatric care or high-intensity treatment needs those services in addition to housing.

How to Prevent the Treatment Plan From Breaking at Discharge

Why a direct handoff is stronger than a referral list

A referral list shifts the burden of arranging care onto someone who may still be fatigued, anxious or cognitively impaired. A direct handoff confirms that the next provider has accepted the patient, knows the medication plan and has an appointment scheduled.

Transportation and insurance authorization are part of continuity. A clinically good plan can fail if the patient cannot physically get to it.

What if the original plan falls through?

A residential bed may disappear, insurance authorization may be delayed or the patient may decide they do not want the recommended program. The treatment plan should not collapse completely.

The team can identify the safest available alternative, such as medication treatment, high-intensity outpatient care, recovery housing or another provider, while continuing to pursue the preferred level.

What if the patient returns to use?

Return to use should trigger reassessment, not abandonment. The treatment intensity, medication strategy, environment and relapse plan may need to change.

For opioids, overdose prevention becomes immediately important. If opioid use recurs after reduced tolerance, naloxone access and rapid re-engagement with MOUD are high priorities.

What Long-Term Recovery Management Needs to Include

Co-occurring mental health treatment

Depression, trauma symptoms, psychosis, bipolar disorder or anxiety may become more visible after acute intoxication resolves. Some symptoms are substance induced and improve with abstinence; others reflect an independent condition.

ASAM’s current standards expect addiction treatment to account for co-occurring mental-health needs rather than requiring every psychiatric symptom to disappear before substance-use treatment can continue.

Family role

With patient consent, family can help with transportation, medication pickup, appointment reminders and making the home environment safer. They can also learn overdose warning signs and where naloxone is stored when opioids are involved.

Family should not become the medication prescriber, therapist or police force. Support works better when roles are clear.

How to tell whether the next step is working

Useful markers include treatment attendance, medication adherence, reduced or absent substance use, improved sleep and daily functioning, psychiatric stability, fewer emergency episodes and a safer recovery environment.

A treatment plan should be reassessed if the patient repeatedly misses care, returns to use, becomes more depressed or psychotic, or cannot remain safe in the current setting.

Why treatment does not end at 30 days

ASAM’s Fourth Edition explicitly supports a chronic-care model, including long-term remission monitoring. Addiction risk can change over time, and treatment intensity can increase again if recurrence occurs.

This model is more realistic than treating a single detox or 30-day rehab episode as the end of care.

What a Strong Discharge Plan Looks Like on Paper

A discharge plan should be specific enough that another clinician could understand the next step without calling the detox unit for clarification. It should list the next provider, appointment time, medication list, current taper or MOUD status, overdose-prevention plan, psychiatric follow-up and housing destination.

It should also document what happens if the preferred plan fails. A patient who is denied a residential bed should not be left with no treatment. The fallback may be a medication appointment, high-intensity outpatient program, recovery residence or another provider while placement continues.

A practical discharge checklist

• Next appointment is scheduled
• Transportation is arranged
• All medications and prescribers are clear
• Buprenorphine or methadone continues if indicated
• AUD medication has been considered when appropriate
• Naloxone is available when opioid risk is present
• Psychiatric follow-up is arranged when needed
• Housing plan is safe enough for the next level
• Emergency and recurrence plan is understood

Frequently Asked Questions About What Happens After Detox

Do most people go to rehab after detox?

Many do, but the correct next level may be residential or outpatient depending on the patient’s clinical needs and environment.

Can medication continue after detox?

Yes. Buprenorphine, methadone, AUD medication, psychiatric medication and some tapers may continue after withdrawal management.

Why is opioid overdose risk important after detox?

Tolerance can fall during abstinence, so return to a previously tolerated amount can increase overdose danger.

Is sober living the same as rehab?

No. Recovery housing provides a living environment; clinical treatment may still be needed separately.

What if someone relapses right after detox?

They should be reassessed and re-engaged in treatment quickly, with special attention to overdose prevention for opioids.

Sources

• The ASAM Criteria, Fourth Edition: current continuum of care, level-of-care assessment, reassessment and integration of withdrawal management into the broader addiction-treatment continuum.
• ASAM Criteria FAQ: current Fourth Edition withdrawal-management mapping, inpatient vs residential distinctions and least-intensive-safe-level principles.
• SAMHSA Evidence-Based Practices Resource Center: TIP 45: evaluation, stabilization and transition into continuing substance-use treatment.
• SAMHSA Treatment Options for Substance Use Disorder: medications, behavioral treatment and individualized treatment-setting selection.

Medication Sources

• SAMHSA TIP 63: Medications for Opioid Use Disorder: buprenorphine, methadone and naltrexone treatment.
• SAMHSA: Medications, Counseling, and Related Conditions: current AUD and OUD medication overview.
• ASAM Alcohol Withdrawal Management Guideline: ambulatory and inpatient withdrawal treatment and transition into AUD care.
• Joint Clinical Practice Guideline on Benzodiazepine Tapering, 2025: individualized gradual tapering and avoidance of abrupt discontinuation in physically dependent patients.
• FDA: Lofexidine approval information: lofexidine is indicated to mitigate opioid-withdrawal symptoms to facilitate opioid discontinuation in adults.